Trial Profile
Effects of different concentrations of dexmedetomidine on basal ganglia neuronal activity (local field potentials) in Parkinson's disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Apr 2021
Price :
$35
*
At a glance
- Drugs Dexmedetomidine (Primary)
- Indications Parkinson's disease
- Focus Therapeutic Use
- 23 Apr 2021 Status changed from recruiting to completed
- 23 Apr 2021 Results evaluating and quantifing the effect of increasing dexmedetomidine doses on subthalamic nucleus activity activity in patients with PD and STN-DBS electrodes, published in the British Journal of Anaesthesia
- 29 Dec 2018 The study has been completed in the Spain, according to European Clinical Trials Database.